Leading Health and Life Sciences in Nova Scotia

News Release: DSM launches new 3C Technology to reinvigorate Omega-3 supplements category


Tailored Omega-3 EPA + DHA high concentrates become the new standard

DSM, a global science-based company active in health, nutrition and materials, is launching a new process technology at this year’s Supply Side West (SSW) trade show in Las Vegas on 6thOctober. The unique 3C technology delivers highly-concentrated (up to 85%) and customizable combinations of EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) for both pharmaceutical and dietary supplement applications, while providing peace of mind through a consistent supply chain. DSM 3C Technology is a radically efficient process technology that makes high-concentrate omega-3 EPA + DHA more accessible and relevant to consumers to build a brighter future. This technology will be a catalyst for category growth by helping to eliminate key barriers to consumption of omega-3 supplements such as capsule size. In addition, it provides brand owners with the versatility to innovate tailored health-focused products to meet consumer needs across a lifetime. “A large and growing body of evidence shows that insufficient levels of omega-3 EPA + DHA may be associated with serious health complications for many Americans,” said Michael McBurney, PhD, FACN, VP of Science, Communications and Advocacy, DSM Nutritional Products1. Low levels of omega-3 are related to increased risk of cardiovascular disease, which is the leading cause of death among both men and women in the United States2,3. Currently, 95.7% of Americans are not consuming enough omega-3 EPA + DHA to reach cardioprotective levels4. DSM has kicked off the “Modern Movement Forward” marketing campaign to inspire category change through 3C technology. “This new technology truly makes the oversized pills of traditional fish oil with low EPA & DHA omega 3 content a thing of the past,” said Tobe Cohen, Vice President, DSM Nutritional Products. The campaign will be brought to life at the DSM booth, #GG 143 at SSW and through digital & print media. Visitors will learn more about a new line of next generation omega-3, called MEG-3® Ultra produced with 3C Technology.

Learn More

To learn more about DSM 3C Technology, visit booth# GG 143 and register for the “Technology to Ignite Growth” lunch session on 06/10/16 with special keynote speaker, Kevin Harrington the original Shark on ABC’s EMMY-winning hit show Shark Tank. To register for this event, please email Jessica Barreras at [email protected]. More information can also be found at www.dsm.com/human-nutritionand www.meg-3.com.]]>

Life Sciences offers solutions for growth in Nova Scotia after 2016-17 budget release

NEWS RELEASE HALIFAX, April 21, 2016 — On Tuesday the Nova Scotia government tabled its 2016-17 Budget with a surplus of $17.1 million and a commitment to work collaboratively with industries with big potential in the province. As part of the Budget address, the province called for a collaborative approach model to boost the economy. “This government understands that we cannot solve our economic problems alone. We need to work together to create a stronger economy, a stronger Nova Scotia,..” stated the- Hon. Randy Delorey, Minister of Finance as part of Budget 2016-2017 The life sciences industry in Nova Scotia has indicated it is ready to work with government and is poised as a growth facilitator for the province’s future economic and social prosperity. Generating nearly $300 million in revenues for the province and exporting up to 90% of products, the sector offers a strong and sustainable economic strategy. “With further support from the province for the life sciences community to develop their ideas, commercialize their technologies and build links within the region and internationally we will continue to be a wealth generator for the province,” said Scott Moffitt, Managing Director of BioNova, the life science industry association. The industry has also been fostering valuable collaborative relationships with national associations such as Innovative Medicines Canada to accelerate the development of local pharmaceutical companies, as evidenced by the recent signing of a memorandum of understanding to enhance Nova Scotia’s medical technology portfolio. In recent years, the local life sciences industry has also seen a significant increase in innovation and potential coming from Nova Scotia companies. Immunovaccine Inc. is a good example of this, with a greater than $60 million market cap and a new CEO focused on industry collaborations to continue down the path of growth. The $540 million acquisition of Nova Scotia-based Ocean Nutrition Canada by Royal DSM, a global life science and material sciences company, is another example of growth in the sector. “It’s easy to imagine what more growth in this sector could lead to for Nova Scotians. We look forward to building strong links with the Government of Nova Scotia to further innovation in Nova Scotia’s life sciences sector,” said Russell Williams, President of Innovative Medicines Canada. ABOUT BIONOVA BioNova is Nova Scotia’s life sciences industry association and sector development organization. BioNova leads and supports its members as we build a successful, self-sustaining life sciences industry in Nova Scotia. By promoting the industry and its successes, building relationships both inside and outside the province and creating networking and educational opportunities BioNova aims to accelerate the commercialization success of Nova Scotia’s life sciences businesses and organizations. ABOUT INNOVATIVE MEDICINES CANADA Innovative Medicines Canada is the national voice of Canada’s innovative pharmaceutical industry. We advocate for policies that enable the discovery, development and commercialization of innovative medicines and vaccines that improve the lives of all Canadians. We support our members’ commitment to being valued partners in the Canadian healthcare system.   – 30 – For further information: Shana McRae Marketing & Communications Officer, BioNova Telephone: 902-421-5705 ext. 2 E-mail: [email protected] Sarah Douglas Media Relations, Innovative Medicines Canada Telephone: 613-883-7250 E-mail: [email protected]]]>